You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
澤璟製藥(688266.SH):與廣東開拓就雙特異抗體新藥GS19簽署獨家許可協議
格隆匯 08-20 18:37

格隆匯 8 月 20日丨澤璟製藥(688266.SH)公佈,公司控股子公司Gensun Biopharma, Inc. (GENSUN)與開拓藥業(廣東)有限公司(“廣東開拓”)2020820就雙特異抗體新藥GS19簽署《獨家許可協議》,與廣東開拓進行合作開發並授予其在大中華區(包括中國大陸、香港、澳門和台灣)的專利獨家授權

GENSUN為公司控股子公司,公司通過全資子公司Zelgen Holdings Limited(中文名稱:澤璟控股有限公司)間接持有GENSUN經完全攤薄(考慮GENSUN股權激勵計劃預留股份)後51%的股份。GENSUN目前在研10餘個臨牀前項目,專注於研發腫瘤免疫治療和腫瘤免疫微環境調節抗體藥物的研發。

GS19是一款針對PD-L1TGF-β的雙靶點抗體,具有同時抑制PD-L1TGF-β的高度活性。經過基因工程修飾能夠降低其在CHO細胞表達蛋白中的降解或片段化,更易於商業化生產。GENSUN擁有GS19全球知識產權。

付款Kintor Science Limited(持有廣東開拓100%股權)就此項授權許分別向GENSUN支付如下許可費:首次付款《獨家許可協議》簽署後30天內支付400萬美元里程碑付款:發生《獨家許可協議》約定的里程碑事件後30分批支付合計金額1900萬美元的里程碑款項;開拓藥業將根據GS19在大中華區的年度淨銷售額在許可使用期限內GENSUN支付一定比例的特許權使用費。“許可使用期限”是指根據被許可產品和所在國家的具體情況,從生效日到下述日期的期間,以下述更早日期為準:(a)被許可產品之被許可權利的到期日;(b)許可區域首次商業銷售起8年。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account